The nation’s top drug regulator now sits at the center of a political and public health storm.

Reports indicate Donald Trump has signed off on a plan to remove FDA Commissioner Marty Makary after months of controversy inside the agency and rising frustration among White House allies and Republican lawmakers. The reported move follows a run of decisions on drugs, vaccines and vaping that drew sharp scrutiny, while internal morale reportedly sank amid layoffs and the appointment of officials seen by critics as deeply divisive.

The struggle over the FDA now looks bigger than one commissioner’s future: it reflects a widening clash over how the agency makes decisions, communicates risk and earns public trust.

Makary’s tenure has become a flashpoint because the disputes reach into some of the most politically charged corners of public life. Abortion, vaccine policy, drug approvals and nicotine regulation have all fueled pressure on the agency. Reports also point to concern over pulled-back publications on the safety of shingles and Covid vaccines, as well as broader unease about regulatory choices that critics describe as lacking sufficient supporting data.

Key Facts

  • Reports indicate Trump approved a plan to fire FDA Commissioner Marty Makary.
  • Makary’s tenure has faced criticism over vaccine, drug and vaping decisions.
  • Staff morale at the FDA reportedly fell amid layoffs and controversial appointments.
  • Questions have also emerged over clinical trial standards and other regulatory changes.

The stakes extend far beyond Washington infighting. The FDA shapes how Americans judge the safety of medicines, vaccines and consumer health products, and that authority depends heavily on confidence in the agency’s process. When officials appear to shift standards, retreat from public safety messaging or embrace what critics call “data-free” decisions, the damage can spread quickly through hospitals, pharmacies and family medicine cabinets.

What happens next could redefine both the agency’s leadership and its standing with the public. If the White House moves ahead, the change would open a new chapter in an already volatile debate over science, regulation and politics. Even if Makary stays, the pressure surrounding his leadership signals a deeper problem: rebuilding trust at the FDA may prove harder than replacing any single commissioner.